Winhealth Pharma

Patient comes first, always! We strive to build a patient-centric ecosystem
to provide accessibility and affordability to those in need.

Real
Impact for
the Patients ！

We search globally for breakthrough therapies
to transform lives!

Bringing hope and
solidarity to the patients
living under devastation
and solitude!

Learn more

Audaciously

Audaciously Committed to Building a
Healthier Community

Learn more

Rooted in China, Serving Global Health

WinHealth Pharma has been deeply rooted in the Chinese market for nearly two decades, earning widespread recognition through exceptional commercialization and operational excellence. Driven by innovation, we continuously respond to the diverse and evolving therapeutic needs of healthcare professionals and patients. As we further expand our presence, we are strategically positioned for global growth, creating broader opportunities ahead. Our proprietary medicine division specializes in developing, producing, and commercializing established therapies for disease areas like hematologic cancers and kidney diseases. By introducing proven treatments and continually optimizing our operations, we strive to provide patients with more effective therapeutic options, enhance disease management, and significantly improve their quality of life.

As a leading Contract Sales Organization (CSO), WinHealth Pharma specializes in core therapeutic areas including dermatology and scarring, respiratory and infectious diseases, hepatobiliary and digestive disorders, and cardiovascular diseases. Through strategic partnerships with leading global pharmaceutical companies, supported by our refined operational management system and innovative marketing strategies, we consistently drive the market penetration of high-quality medicines and enhance their clinical value. Our commitment is to deliver comprehensive treatment solutions to healthcare professionals and patients, effectively addressing unmet clinical needs.

Pioneering Smart and Sustainable Manufacturing

Our state-of-the-art facility in Shanghai’s Zhangjiang Hi-Tech Park spans nearly 43,000 m² and sets the standard for smart and sustainable manufacturing. By seamlessly integrating drug development, production, warehousing, and logistics, it features GMP-compliant production lines alongside a fully automated, multi-tier warehouse. Leveraging intelligent management systems and lean workflows, we continuously boost efficiency and responsiveness to shifting market demand—ensuring a reliable supply. Committed to environmental stewardship, the site has deployed solar arrays and other cutting-edge energy-saving technologies to reduce emissions and maximize resource utilization, supporting our long-term sustainability goals.

Corporate Social Responsibility

Battling against Covid-19 Pandemics

As a biopharma corporation, we believe that it's our essential responsibility to make meaningful contributions to the fight against Covid-19 Pandemics together with hundreds of generous Winhealthers. We have acted with speed and contributed to the battle against the Pandemics on multiple fronts.

Hong Kong Winhealth Pharma Group Co, Ltd donated CNY500,000 to support Wuhan

To ensure the drug supply chain operates, related communication and coordination work functions and emergencies can be timely handled during the Spring Festival. The company's leaders decided to urgently set up a 'temporary special emergency team' on January 24, 2020. In addition, a decision was made to donate CNY500, 000 to relevant medical institutions in Wuhan City through the Red Cross Society to fight against Covid-19.

Learn more

Corporate Social Responsibility

Project Rainbow

Winhealth has been supporting the "Project Rainbow" for 3 consecutive years and provides life supports to nearly 100 children. Their hope is our future.

Adhering to the original intention of public welfare, Winhealth has paired with 70 underprivileged children.

The year of 2020 is the final year of the fight against poverty and the building of a moderately prosperous society in all respects, and it is also the third year for Winhealth Pharma to participate in the public welfare education assistance action of "Project Rainbow". Committed to its original intention of public welfare, Winhealth Pharma has actively assumed its corporate social responsibility and worked hard on the path of poverty alleviation.

Learn more

Battling against Covid-19 Pandemics

Project Rainbow

News & Media

Hong Kong Winhealth Pharma Group Successfully Completes Equity Acquisition of Kyowa Kirin China, Ushering in a New Chapter of Development. 2024-10-08

Winhealth Pharma's licensed Difelikefalin injection significantly improves pruritus associated with chronic kidney disease in hemodialysis patients in Phase III clinical study in China 2024-09-04

Hong Kong WinHealth Pharma Group Announces Acquisition of Kyowa Kirin Subsidiary 2024-08-02

Winhealth Pharma and Ferring Pharmaceuticals have reached a strategic collaboration on Pentasa®, which will be used to treat inflammatory bowel disease. 2022-06-01

Medication Made Available to HGPS Patients! Winhealth Pharma Contributing to the “Public Welfare Program for Treatment of Children with HGPS” 2022-04-23

Expert Consensus on Treatment of Acne Scars in China (2021) Officially Unveiled 2021-12-30

Learn more

Relevant search

Company

Patients

Medicines

Business

News & Media

Careers

Contact Us